What is Aphios?
Aphios operates at the intersection of biotechnology and sustainable manufacturing, developing advanced technology platforms. These platforms are designed to enhance drug discovery processes, enable sophisticated nanotechnology drug delivery systems, and improve the safety of therapeutics against pathogenic threats. The company's strategic focus extends to creating improved treatments for chronic conditions such as cancers, infectious diseases like HIV/AIDS, and central nervous system disorders, all while adhering to environmentally responsible practices.
How much funding has Aphios raised?
Aphios has raised a total of $243K across 2 funding rounds:
Debt
$150K
Other Financing Round
$93K
Debt (2020): $150K with participation from PPP
Other Financing Round (2022): $93K, investors not publicly disclosed
What's next for Aphios?
With the infusion of substantial expansion capital, Aphios is poised for significant operational scaling and further development of its therapeutic pipeline. The company's commitment to green biotechnology and its focus on addressing critical unmet medical needs position it for continued investment and strategic partnerships. Future endeavors will likely concentrate on advancing its drug candidates through clinical trials and expanding its manufacturing capabilities to meet growing market demand for sustainable and effective treatments.
See full Aphios company page
